- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.04. | NEURIZON THERAPEUTICS LIMITED: Section 708A Cleansing Statement | 3 | ASX | ||
| 01.04. | NEURIZON THERAPEUTICS LIMITED: Application for quotation of securities - NUZ | - | ASX | ||
| 01.04. | NEURIZON THERAPEUTICS LIMITED: NUZ-001 Data Shows Multi-Pathway Protein Clearance | 2 | ASX | ||
| 25.03. | NEURIZON THERAPEUTICS LIMITED: Change of Director's Interest Notices x4 | 2 | ASX | ||
| 19.03. | NEURIZON THERAPEUTICS LIMITED: Notification of Expiry of NUZOA Listed Options | 2 | ASX | ||
| 19.03. | NEURIZON THERAPEUTICS LIMITED: Neurizon presents at HEALEY ALS Platform Trial Webinar | - | ASX | ||
| NEURIZON THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 19.03. | NEURIZON THERAPEUTICS LIMITED: Section 708A Cleansing Statement | 4 | ASX | ||
| 19.03. | NEURIZON THERAPEUTICS LIMITED: Application for quotation of securities - NUZ | 1 | ASX | ||
| 15.03. | NEURIZON THERAPEUTICS LIMITED: Neurizon announces leadership transition | 1 | ASX | ||
| 05.03. | NEURIZON THERAPEUTICS LIMITED: Preclinical Data in Huntington's Disease Presented at ASENT | 6 | ASX | ||
| 03.03. | NEURIZON THERAPEUTICS LIMITED: Notification of cessation of securities - NUZ | - | ASX | ||
| 27.02. | NEURIZON THERAPEUTICS LIMITED: Drawdown of tranche one of strategic financing facility | 3 | ASX | ||
| 27.02. | NEURIZON THERAPEUTICS LIMITED: Notification regarding unquoted securities - NUZ | 1 | ASX | ||
| 26.02. | NEURIZON THERAPEUTICS LIMITED: Cleansing Statement - Section 708A(12C)(e) | 1 | ASX | ||
| 26.02. | NEURIZON THERAPEUTICS LIMITED: Application for quotation of securities - NUZ | - | ASX | ||
| 26.02. | NEURIZON THERAPEUTICS LIMITED: Section 708A Cleansing Statement | - | ASX | ||
| 26.02. | Neurizon doses first patient with NUZ-001 in amyotrophic lateral sclerosis trial | 4 | The Market Herald Australia | ||
| 25.02. | NEURIZON THERAPEUTICS LIMITED: Neurizon Initiates Dosing in HEALEY ALS Platform Trial | - | ASX | ||
| 24.02. | NEURIZON THERAPEUTICS LIMITED: Appendix 4D - Half-year Financial Report - 31 December 2025 | 3 | ASX | ||
| 20.02. | NEURIZON THERAPEUTICS LIMITED: Results of General Meeting | 1 | ASX |
1 2 3 4 Weiter >>
73 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 23,580 | +0,15 % | Pfizer walks away from 'underutilized' office space in South San Francisco, transitions employees to remote roles | ||
| NOVARTIS | 130,98 | -0,94 % | Novartis To Expand Community Health Programs To Over 30 Countries By 2030 | BASEL (dpa-AFX) - Novartis AG (NVS) on Thursday announced plans to significantly expand its community health programs aimed at improving access to diagnosis and treatment for heart disease and... ► Artikel lesen | |
| GILEAD SCIENCES | 121,84 | +0,45 % | BREAKING: Für bis zu 5 Milliarden Dollar! Gilead kauft Biotech-Firma aus München | Das Übernahme-Karussell im Biotech-Sektor dreht sich gefühlt von Woche zu Woche immer schneller. Erst am Ostermontag hat Neurocrine Biosciences die milliardenschwere Übernahme von Soleno Therapeutics... ► Artikel lesen | |
| ROCHE | 339,96 | -0,67 % | Morgan Stanley senkt Roche-Kursziel wegen Währungseffekten auf 46 US-Dollar | ||
| STADA ARZNEIMITTEL | - | - | CapVest Partners LLP: CapVest schließt Übernahme der Mehrheitsanteile an Stada ab | CapVest Partners LLP ("CapVest"), eine weltweit führende Investmentgesellschaft, gibt heute den Abschluss der Übernahme der Mehrheitsanteile an der STADA Arzneimittel AG ("STADA" oder das "Unternehmen")... ► Artikel lesen | |
| TEVA | 26,000 | -0,76 % | Teva Pharmaceutical Industries Limited (TEVA): Billionaire Stan Druckenmiller Trims Position | ||
| DIGICANN VENTURES | 0,004 | 0,00 % | Digicann Ventures Inc.: Digicann Ventures Announces Resignation of Director | Vancouver, British Columbia--(Newsfile Corp. - April 8, 2026) - Digicann Ventures Ltd. (CSE: DCNN.X) ("Digicann" or the "Company"), a company focused on opportunities within and outside of the cannabis... ► Artikel lesen | |
| EYEPOINT | 12,000 | 0,00 % | EyePoint, Inc.: EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments | - Both pivotal Phase 3 trials for DURAVYU in wet AMD on track for data readout beginning in mid-2026 - - Patients dosed in both COMO and CAPRI Phase 3 clinical trials for DURAVYU in DME -... ► Artikel lesen | |
| GREEN THUMB INDUSTRIES | 5,740 | -0,86 % | RYTHM, Inc. Announces Amendments to License Agreements with Green Thumb Industries | ROLLING MEADOWS, Ill., April 01, 2026 (GLOBE NEWSWIRE) -- RYTHM, Inc. (Nasdaq: RYM) ("RYTHM" or the "Company"), America's THC Company, today announced amendments to its existing trademark and recipe... ► Artikel lesen | |
| IONIS PHARMACEUTICALS | 64,72 | +0,72 % | EU Approves DAWNZERA For Hereditary Angioedema, Says Ionis And Otsuka | TOKYO (dpa-AFX) - Ionis Pharmaceuticals, Inc. (IONS) and Otsuka Pharmaceutical Co., Ltd. on Wednesday said the European Commission has approved Dawnzera to prevent repeated attacks of hereditary... ► Artikel lesen | |
| SINOPHARM | 2,281 | -2,56 % | Reed Sinopharm Exhibitions (RSE): PCHi 2026: World's Largest Cosmetics Ingredients Exhibition Opens in Hangzhou | 860+ exhibitors from 26 countries and regions across 70,000 sqmClose to 50 new product launches, including global and China debuts295 product submissions and 19 engineer nominations for the... ► Artikel lesen | |
| ASSEMBLY BIOSCIENCES | 25,400 | +0,79 % | Assembly Biosciences und der 40-Milliarden-Dollar-Markt - Übernahme-Rallye voraus? | Die Aktie von Assembly Biosciences gehört derzeit zu den auffälligsten Diskrepanzen zwischen wissenschaftlichem Potenzial und Börsenbewertung im Biotechnologiesektor. Während das Unternehmen an neuartigen... ► Artikel lesen | |
| CSPC PHARMA | 1,039 | +1,39 % | CSPC PHARMA (01093): UPDATE ANNOUNCEMENT - CONNECTED TRANSACTION IN RELATION TO THE DISPOSAL OF 30.0704% EQUITY INTEREST IN THE TARGET COMPANY | ||
| ALNYLAM PHARMACEUTICALS | 278,30 | -0,57 % | Alnylam Pharmaceuticals (ALNY) Presents Vutrisiran ATTR-CM Data at ACC.26 | ||
| NEKTAR THERAPEUTICS | 66,12 | +2,77 % | Nektar Therapeutics: Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting | Rezpegaldesleukin demonstrates statistically significant improvement in mean percent EASI improvement across both moderate and severe atopic dermatitis patients
Rezpegaldesleukin... ► Artikel lesen |
NEURIZON THERAPEUTICS LIMITED gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell +5,06 % bei einem Aktienkurs von 0,042 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEURIZON THERAPEUTICS LIMITED finden Sie auf Wallstreet Online.